OAA0306 | Protective efficacy of a vaccine inducing Gag/Vif-specific CD8+ T but not CD4+ T cells against repeated intrarectal low-dose SIVmac239 challenges | Oral abstract session with live Q&A | A27 |
OAALB0102 | HIV envelope BG505 SOSIP immunization induces autologous virus and CD4 binding site-specific B cell lineage antibody precursor responses in infant rhesus macaques | Oral abstract session with live Q&A | A26 |
OAA0304 | Priming with DNA expressing trimeric V1V2A244 alters the immune hierarchy and favors the development of V2-specific HIV antibodies in rhesus macaques | Oral abstract session with live Q&A | A25 |
OAA0305 | Sequence and structure guided HIV-1 clade C trimeric immunogen design to induce neutralizing and V1V2 directed antibody responses | Oral abstract session with live Q&A | A25 |
OAALB0101 | Induction of cross-neutralizing antibodies and protection from heterologous tier-2 SHIV challenge by an mRNA-based vaccine in macaques | Oral abstract session with live Q&A | A25 |
OAALB0104 | Vaccination against HIV-1 with interbilayer cross-linked multilamellar vesicles carrying SOSIP trimer | Oral abstract session with live Q&A | A25 |
OAALB0103 | CCR5 antibody blockade protects rhesus macaques from rectal SHIV acquisition | Oral abstract session with live Q&A | A24 |
PDA0207 | Interferon-a modulates the host glycosylation machinery during treated HIV infection | Poster exhibition | A24 |
PEA0066 | A pilot study: CRISPR/Cas9 therapy for an effective control of genetically diverse HIV-1 | E-poster | A23 |
LBPEA01 | Long-acting starch nanoparticle drug delivery system to treat chronic HIV | E-poster | A22 |